Life science company Verily has introduced Lightpath, an AI-powered chronic care solution. The initial offering, Lightpath Metabolic, focuses on helping people with cardiometabolic conditions and targets open enrollment for early 2026.

Lightpath Metabolic offers personalized care plans for individuals leveraging clinical expertise and advanced data analysis. It also uses AI to enhance member engagement and support for clinical staff. Key features include modular programs such as 1) Metabolic Intensive for diabetes management, 2) Weight Loss Intensive with anti-obesity medications, 3) Metabolic Improvement for diabetes prevention, and 4) Metabolic Achievement for long-term support.

The new solution builds on the success of Verily's existing solution, Onduo, which focuses on managing people with diabetes and other chronic conditions. Further, Verily plans to offer Onduo users the option to migrate to Lightpath Metabolic in late 2025.